Yahoo Finance

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
Yahoo Finance

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection

NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...
FiercePharma

Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis

The patent covers intermediate compounds and processes for the preparation of Fingolimod NESS ZIONA, Israel, Feb 18, 2014 (BUSINESS WIRE) -- Mapi Pharma Ltd. ("Mapi" or the "Company"), a developer of ...
Business Wire

ICON Acquires Mapi Group

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that ...
Nasdaq

Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial

NESS ZIONA, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, today announced that patient enrollment has surpassed 60% in ...
FiercePharma

Mapi incorporates Strategic Regulatory Services to support life-science product Commercialization and Health Research

Yardley, Pennsylvania—3 March 2015 – Mapi incorporates the expertise of CanReg in supporting our clients Regulatory challenges through the drug development and commercialization process. Mapi Group ...